louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03231696: Visibility - Classification of Sono-visibility of Anatomical Structures in Peripheral Nerve Blocks
Official title: Visibility - A Novel Classification Score of Sono-visibility of Anatomical Structures in Peripheral Nerve Blocks
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia, Local
Anesthesia
Keywords: nerve block
peripheral nerve stimulation
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2017-07-27
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.

Brief summary: We assessed the visibility of peripheral nerves while ultrasound guided blockades with a novel scoring system to evaluate differences in visibility of different nerves.

Detailed description: We assessed the visibility of peripheral nerves while ultrasound guided blockades with a novel scoring system to evaluate differences in visibility of different nerves.

VIS(visibility) 1 easy identification and instant visualisation of all structures VIS 2 identification and visualisation of all structures after some corrections VIS 3 identification and visualisation of structures only unsure VIS 4 identification and visualisation of all structures impossible VIS 5 no structures seen. We amended a sub-project in which assessed the visibility in protective nerve stimulated nerve blocks in 46 patients.

Eligibility criteria: Inclusion Criteria (study sample N=1200):

* peripheral nerve block by ultrasound guidance
* age ≥ 18 years

Exclusion Criteria:

* contraindications for regional anesthesia

Inclusion Criteria (study sample as of amendment n=46):

* peripheral nerve block by ultrasound guidance
* age ≥ 18 years

Exclusion Criteria:

* contraindications for regional anesthesia (study sample n=46)
* using not the standard ultrasound machine
* performing not a standard regional anesthesia

Primary outcomes:
measure: Visibility
timeFrame: During regional block (an average of 1 hour)
Secondary outcomes:
measure: Additional analgesia
timeFrame: During surgery (an average of 4 hours)
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Department of Anesthesiology and Operative Intensive Care Medicine, CCM and CVK
Study officials:
affiliation: Department of Anesthesiology and Operative Intensive Care Medicine, CCM and CVK
name: Jürgen Birnbaum, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06389396: Investigation of a New Rectal Catheter for Users of Transanal Irrigation
Official title: Investigation of a New Rectal Catheter for Users of Transanal Irrigation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bowel Management
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2024-04-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The clinical investigation is an exploratory, randomised controlled, open-labelled, crossover investigation.

The clinical investigation will be conducted as a multi-centre clinical investigation in two different clinical investigation sites in Denmark.


Eligibility criteria: Inclusion Criteria:

1. Has given written Informed Consent
2. Is at least 18 years old
3. Has full legal capacity
4. Has used Trans Anal Irrigation (TAI) with balloon catheter for at least 4 weeks prior to inclusion
5. Performs TAI minimum 3 times/week
6. Is able to follow study procedures assessed by investigator

Exclusion Criteria:

1. Has known anal or colorectal stenosis
2. Has active/recurrent colorectal cancer
3. Is within 3 months of anal or colorectal surgery
4. Is within 4 weeks of endoscopic polypectomy
5. Has ischaemic colitis
6. Has acute inflammatory bowel disease
7. Has acute diverticulitis
8. Is participating in any other clinical study that may interfere with this study (assessed by investigator).
9. Is pregnant or breastfeeding

Primary outcomes:
measure: Was it Possible to Perform Transanal Irrigation?
timeFrame: Evaluated at Visit 1 and Visit 2 (within a time duration of up to 17 days)
Secondary outcomes:
Other outcomes:
Locations:
city: Århus
country: Denmark
facility: Århus Universitetshospital
state: Jutland
city: Hvidovre
country: Denmark
facility: Amager Hvidovre Hospital
state: Zealand
Study officials:
References:
Clinical trial NCT06031896: The Severity of Periodontitis at the Buccal and Palatal Site
Official title: The Comparison of the Severity of Periodontitis at the Buccal and Palatal Site
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Periodontal Diseases
Lead sponsor: The Dental Hospital of Zhejiang University School of Medicine
Sponsor class: OTHER
First posted: 2023-09-11
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: As many patients as investigators can collect

Brief summary: To record and compare the periodontal conditions of buccal and palatal sites in patients


Eligibility criteria: Inclusion Criteria:

* patients with diagnosed periodontitis

Exclusion Criteria:

* compromised systematic health (uncontrolled hypertension, diabetes, impaired bone metabolism condition, etc.), uncontrolled periodontal disease, smoking \> 20 cigarettes/day or recent chemotherapy/radiotherapy in the oral and maxillofacial regions

Primary outcomes:
measure: probing depth
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The Affiliated Hospital of Stomatology, Zhejiang University School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT03490916: Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
Official title: A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: High Altitude Pulmonary Edema
Keywords: Acetazolamide
High-altitude illness
High-altitude pulmonary edema
Lung comets
Lung ultrasound
Subclinical high-altitude pulmonary edema
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
First posted: 2018-04-06
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.


Eligibility criteria: Inclusion Criteria:

1. At least 18 years of age
2. Able to consent
3. English speaking
4. Trekking directly to Everest Base Camp

Exclusion Criteria:

1. Age less than 18 years
2. Non-English speaking
3. Pregnant
4. Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema
5. Been on a high-altitude trek 2 weeks prior to this study
6. Has taken acetazolamide 1 week prior to start of trek
7. Has a sulfa allergy
8. Has any type of acute or chronic pulmonary conditions

Primary outcomes:
measure: Pulmonary Edema Before and After Taking Acetazolamide
timeFrame: 1 month
Secondary outcomes:
measure: Time to Completion of Ultrasound Exams
timeFrame: 1 month
Other outcomes:
Locations:
city: Worcester
country: United States
facility: UMass Medical School
state: Massachusetts
Study officials:
affiliation: University of Massachusetts, Worcester
name: Hillary Irons, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03646916: Intraoperative Dexamethasone and Its Effect on Hyperglycemia
Official title: Effect of Pre-Operative Dexamethasone Dose on the Post-Operative Management of Blood Sugar in Diabetic Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Diabetes Mellitus
Lead sponsor: Ascension Health
Sponsor class: INDUSTRY
First posted: 2018-08-24
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To study the effect of intra-operative dexamethasone on the management of post-operative blood sugar in diabetic patients.


Eligibility criteria: Inclusion Criteria:

* documented history of Type I or Type II Diabetes Mellitus
* scheduled for surgery that requires patients to be admitted for at least 24 hours post-surgery

Exclusion Criteria:

* Patients on steroid therapy
* Pregnant women
* Patients at low risk for nausea/vomiting

Primary outcomes:
measure: Post-operative blood sugar
timeFrame: 24 hour Post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Grand Blanc
country: United States
facility: Genesys Regional Medical Center
state: Michigan
Study officials:
References:
Clinical trial NCT03761316: Goal Setting in SCS Patients: a Qualitative Review
Official title: Goal Setting in SCS Patients: a Qualitative Review (LEISURE)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Failed Back Surgery Syndrome
Keywords: Spinal cord stimulation
interview
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: Medtronic
First posted: 2018-12-03
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with medication-resistant chronic back and leg pain due to Failed Back Surgery Syndrome who are offered treatment with SCS.

Brief summary: This is a prospective study in which the investigators will describe individual goals of patients with Failed Back Surgery Syndrome, who will be treated with spinal cord stimulation.


Eligibility criteria: Inclusion Criteria:

* Chronic pain as a result of FBSS that exists for at least 6 months with a pain intensity 5 or higher measured on numeric rating scale (NRS)
* FBSS patients suitable for SCS
* Age \> 18 years
* Native Dutch or French speeking patients

Exclusion Criteria:

* Expected inability of patients to receive or properly operate the spinal cord stimulation system
* History of coagulation disorders, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis or morbus Bechterew
* Active malignancy
* Addiction to any of the following drugs, alcohol (5E/day) and/or medication
* Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and/or ability to evaluate treatment outcome as determined by investigator
* Immune deficiency (HIV positive, immunosuppressiva, etc.)
* Life expectancy \< 1 year
* Local infection or other skin disorder at site of incision
* Pregnancy
* Other implanted active medical device

Primary outcomes:
measure: Goals and expectations towards spinal cord stimulation
timeFrame: Before spinal cord stimulation implantation
Secondary outcomes:
Other outcomes:
Locations:
city: Jette
country: Belgium
facility: UZ Brussel
state: Brussel
Study officials:
affiliation: Universitair Ziekenhuis Brussel
name: Maarten Moens, Prof. dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02803216: Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori
Official title: Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori: a Prospective, Double-blinded, Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Helicobacter Pylori Infection
Lead sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sponsor class: OTHER
First posted: 2016-06-16
Enrollment: 576
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of Traditional Chinese Medicine (TCM) decoction and powder combined with standard triple therapy on improving eradication rate of Helicobacter Pylori (H. pylori).A multi-center randomized control clinical trial design was adopted in the trial.


Eligibility criteria: Inclusion Criteria:

* those who met chronic gastritis (chronic superficial gastritis and chronic atrophic gastritis) diagnostic criteria;
* aged between 18-65 years old;
* positive H. pylori infection confirmed by two or more methods of different
* principles (stop using PPI, H2RA, bismuth, and antibiotics since two weeks before examination);
* patients were informed consent and willing to accept corresponding treatments.

Exclusion criteria:

* Patients having chronic atrophic gastritis with severe dysplasia, upper gastrointestinal bleeding, peptic ulcers, and gastrointestinal tumors;
* digestive organic disease (such as chronic pancreatitis, cirrhosis, etc.), or systemic diseases affecting intestinal motility (such as hyperthyroidism, diabetes mellitus, chronic renal insufficiency, mental, and neurological diseases, etc.);
* those who were accompanied by serious heart, liver and other major organs lesions, blood diseases, and cancer (ALT, AST two times higher than normal value);
* those who had taken medicines that might affect H. pylori detection results within two weeks (antacids, H2RA, PPIs, bismuth and antibiotics, etc.);
* pregnant and lactating women; patients with history of systematic and neuropsychiatric disorders; those who had history of any drug allergy; and those who were participating in other clinical trials.

Primary outcomes:
measure: H. pylori eradication rate
timeFrame: 13C or 14C urea breath test was performed at four weeks after western medicine termination.
Secondary outcomes:
measure: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
timeFrame: at baseline, and every week up to four weeks.
Other outcomes:
Locations:
Study officials:
affiliation: XiYuan Hospital of China Academy of Traditional Chinese Medicine
name: xudong Tang, Ph.D
role: STUDY_CHAIR
References:
Clinical trial NCT06409416: Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer
Official title: Identification of Molecular Mechanisms Which Drive Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Lung Neoplasms
Progression
Lead sponsor: Casa Sollievo della Sofferenza IRCCS
Sponsor class: OTHER
Collaborators: name: IRCCS Ospedale San Raffaele
First posted: 2024-05-10
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing surgery for confirmed diagnosis of lung adenocarcinoma

Brief summary: Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. Little is known about the molecular mechanisms governing TCP in lung adenocarcinoma (LUAD), i.e. the most frequent lung cancer subtype. The investigators recently identified prognostic 7-miRNAs/10-mRNAs signatures which accurately identified aggressive LUAD among patients with early-stage disease (Stage I). Furthermore, the investigators showed that such tumors show TCP features i.e. mesenchymal and stem-cell traits, high-metastatic potential. Here, the investigators aim to explore by RNAseq and by immunophenotyping at a single-cell level (scRNAseq/AbSeq), the molecular features of aggressive LUAD to unveil the mechanisms triggering TCP. The investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive LUAD.


Eligibility criteria: Inclusion Criteria:

* patients diagnosed with lung adenocarcinoma
* treatment naive
* undergoing primary surgery

Exclusion Criteria:

* patients with a previous history of cancer
* previously treated by chemio/immuno/radio-therapy

Primary outcomes:
measure: TCP-biomarkers screening in a prospective cohort of lung cancer patients
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03723616: Reactions to Warnings on Hookah Ads
Official title: Exploring Reactions to Health Warnings on Waterpipe Tobacco Ads
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Reactions to Warnings
Hookah Smoking
Keywords: Hookah
Shisha
Tobacco
Narghile
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2018-10-29
Enrollment: 4721
Sex: ALL
Minimum age (years): 18
Maximum age (years): 34
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to help us better understand what kinds of waterpipe tobacco advertisements appeal to young adults as well as to help evaluate and create health warnings that can be placed on waterpipe tobacco advertisements to inform young adults of the risks associated with smoking hookah tobacco.


Eligibility criteria: Inclusion Criteria:

* Young adults who are susceptible to or who are current tobacco smokers (which is defined as at least once in the past month, and using hookah tobacco on at least a monthly basis).
* Must have Internet access for Phase 1 and Phase 2 and have a Turkprime account.
* English speaker

Exclusion Criteria:

* Anyone who is not susceptible to waterpipe tobacco smoking or is not a current waterpipe tobacco smoker
* Anyone who does not have Internet access or a Turkprime account

Primary outcomes:
measure: Perceived Risk as Measured by Questionnaire
timeFrame: up to 45 minutes
measure: Worry about Harms as Measured by Questionnaire
timeFrame: up to 45 minutes
measure: Attitudes toward Waterpipe Tobacco Smoking as Measured by Questionnaire
timeFrame: up to 45 minutes
measure: Intention to Try (for Susceptible Nonsmokers of Waterpipe Tobacco Smokers) or Quit (for Smokers of Waterpipe Tobacco) as Measured by Questionnaire
timeFrame: up to 45 minutes
Secondary outcomes:
measure: Effectiveness of Health Warnings on a 1 to 7 scale
timeFrame: up to 45 minutes
measure: Avoidance / Acceptance of Health Warnings as Measured by Eye Tracking
timeFrame: up to one hour
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Duke University
name: Isaac Lipkus, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04156516: Longitudinal Effects of a Sexual Health Intervention: HEART
Official title: Longitudinal Effects of a Sexual Health Intervention: HEART
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: STD
Adolescent Behavior
Lead sponsor: North Carolina State University
Sponsor class: OTHER
First posted: 2019-11-07
Enrollment: 457
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Randomized Controlled Trial to evaluate the eHealth program, HEART (Health Education and Relationship Training).

Detailed description: Randomized Controlled Trial to evaluate the eHealth program, HEART (Health Education and Relationship Training). Data collection will occur at pretest, posttest, 12m (primary endpoint) and 18m (to look at stability of effects over time).

Eligibility criteria: Inclusion Criteria:

* Current high school student
* Able to read English

Exclusion Criteria:

* Not able to read English

Primary outcomes:
measure: Condom use at last sex
timeFrame: 12 months
measure: Sexual intercourse within the past 12 months
timeFrame: 12 months
Secondary outcomes:
measure: HIV/STD Knowledge
timeFrame: 12 months
measure: Self-efficacy
timeFrame: 12 months
measure: Condom Attitudes
timeFrame: 12 months
measure: Condom Norms
timeFrame: 12 months
measure: Communication intentions
timeFrame: 12 months
measure: Condom use intention
timeFrame: 12 months
measure: sexual assertiveness
timeFrame: 12 months
Other outcomes:
Locations:
city: Raleigh
country: United States
facility: North Carolina State University
state: North Carolina
Study officials:
affiliation: North Carolina State University
name: Laura Widman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00043316: Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
Official title: A Phase I/II Study of Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cystic Fibrosis
Keywords: cystic fibrosis
pulmonary impairment
Lead sponsor: InterMune
Sponsor class: INDUSTRY
First posted: 2002-08-09
Enrollment: 66
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks.

The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.


Eligibility criteria: Key inclusion criteria:

* At least 12 years of age
* Diagnosis of cystic fibrosis with mild to moderate pulmonary impairment
* Must be receiving ongoing chronic treatment with TOBI (inhaled tobramycin) OR not receiving ongoing chronic treatment with TOBI and no use of TOBI or other inhaled antibiotic within 4 weeks prior to study drug administration·
* Other specific diagnostic indicators of CF and other factors must meet minimum requirements.

Primary outcomes:
measure: change in FEV1, sputum bacterial density
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Palo Alto
country: United States
state: California
city: Sacramento
country: United States
state: California
city: San Diego
country: United States
state: California
city: San Francisco
country: United States
state: California
city: Denver
country: United States
state: Colorado
city: Daytona Beach
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
city: Chicago
country: United States
state: Illinois
city: New Orleans
country: United States
state: Louisiana
city: Rochester
country: United States
state: Minnesota
city: New York City
country: United States
state: New York
city: Philadelphia
country: United States
state: Pennsylvania
city: Nashville
country: United States
state: Tennessee
city: Lackland AFB
country: United States
state: Texas
city: Tyler
country: United States
state: Texas
Study officials:
affiliation: InterMune
name: Steve Porter, MD
role: STUDY_DIRECTOR
References: